secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2024-06-26T23:59:59+00:00
Accession:  0001193125-24-168597
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell reports 40% ORR in TNBC from Phase 1 LYL797; expands into ovarian cancer
------------------------------------------------------------------------------

- ORR of 40% and CBR of 60% at 150e6 CAR T dose in relapsed/refractory TNBC (n=5).
- No dose-limiting toxicities in patients without lung involvement; pneumonitis managed with prophylactic steroids.
- CAR T cells enhanced with anti-exhaustion technology showed expansion, infiltration, and persistence in solid tumors.
- Trial expanded to ROR1+ ovarian/endometrial cancer; new trial for multiple myeloma/CLL planned.
- IND submitted for LYL119, next-gen ROR1 CAR T candidate; expected to enter clinic this year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524168597/0001193125-24-168597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000119312524168597/d808272d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-168597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer